Hormone Therapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

The term ‘hormone therapy’ encompasses several distinct clinical applications, each with its own evidence base, guidelines, eligibility criteria, and risk-benefit profile. The three principal contexts in which hormone therapy is used are: (1) menopausal hormone therapy (MHT), also called hormone replacement therapy (HRT), used to relieve symptoms of natural or surgical menopause and provide long-term health benefits; (2) gender-affirming hormone therapy (GAHT), which aligns the hormone environment and secondary sex characteristics of transgender and gender-diverse individuals with their gender identity; and (3) androgen deprivation therapy (ADT), which suppresses testosterone to castrate levels in the management of hormone-sensitive prostate cancer.

These three applications share the common principle of intentionally modifying the body’s hormonal milieu for therapeutic benefit, but differ fundamentally in their objectives, the hormones involved, the clinical populations served, and the evidence base guiding their use.

Historical Context of MHT: Following the Women’s Health Initiative (WHI) trial publications in 2002–2004, MHT prescribing declined dramatically due to widely publicised increases in breast cancer and cardiovascular disease risk. Subsequent reanalysis of the WHI data — demonstrating that risks were substantially modified by age, years since menopause, and hormone formulation — has led to a major reassessment. The British Menopause Society (BMS), NICE, and the International Menopause Society (IMS) now support a nuanced, individualised approach in which the benefits of MHT significantly outweigh risks for the majority of symptomatic women under age 60 or within 10 years of menopause onset, particularly with transdermal estradiol and micronised progesterone.

Historical Context of GAHT: Evidence-based gender-affirming hormone therapy for transgender and gender-diverse individuals has expanded substantially in the past two decades, culminating in the WPATH Standards of Care Version 8 (SOC8, 2022) — the most comprehensive international guideline to date — which provides detailed hormone protocols, monitoring recommendations, and criteria for care across the lifespan, including adolescents.

Historical Context of ADT: Androgen deprivation therapy for prostate cancer has been available since Charles Huggins and Clarence Hodges demonstrated in 1941 that prostate cancer regression follows orchidectomy — a discovery that earned Huggins the 1966 Nobel Prize in Physiology or Medicine. Modern ADT uses pharmacological GnRH agonists and antagonists to achieve medical castration.

Hormone therapy addresses three distinct clinical categories:

1. Menopausal Symptoms (MHT/HRT): The menopause — defined as 12 consecutive months of amenorrhoea due to ovarian follicular depletion — causes a dramatic decline in ovarian oestrogen production. This oestrogen deficiency drives a wide range of symptoms including vasomotor symptoms (hot flushes and night sweats, which affect 60–80% of women), urogenital atrophy (vaginal dryness, dyspareunia, recurrent urinary tract infections), sleep disturbance, mood changes, cognitive fogginess, joint pains, and reduced libido. MHT is the most effective treatment for menopausal vasomotor symptoms, with placebo-controlled trials demonstrating a 70–90% reduction in flush frequency and severity. It also prevents the osteoporosis, increased fracture risk, and accelerated cardiovascular risk that accompany oestrogen deficiency, particularly when MHT is initiated within 10 years of menopause (‘the timing hypothesis’ or ‘window of opportunity’).

Premature Ovarian Insufficiency (POI): Women with POI (ovarian failure before age 40, affecting approximately 1% of women) have particularly strong indications for MHT due to the prolonged duration of oestrogen deficiency and its consequences for cardiovascular health, bone density, cognitive function, and sexual wellbeing. In POI, MHT is recommended until at least the average age of natural menopause (approximately 51 years) by NICE, the BMS, and the European Society of Human Reproduction and Embryology (ESHRE).

2. Gender Dysphoria and Gender Incongruence (GAHT): Gender dysphoria — the clinically significant distress arising from incongruence between a person’s experienced/expressed gender and their sex assigned at birth — can be substantially alleviated by gender-affirming hormone therapy, which induces physical changes consistent with the person’s gender identity. GAHT is used for transgender women (MTF — male to female), transgender men (FTM — female to male), and non-binary individuals who desire partial or full hormonal feminisation or masculinisation.

3. Hormone-Sensitive Prostate Cancer (ADT): Prostate cancer cells express androgen receptors and depend on testosterone and dihydrotestosterone (DHT) for growth. ADT reduces circulating testosterone to castrate levels (below 50 ng/dL [1.7 nmol/L]) and is used in: locally advanced prostate cancer (T3-T4, N0-N1); in combination with external beam radiotherapy for intermediate-risk and high-risk localised disease; metastatic (stage M1) hormone-sensitive prostate cancer; and castration-resistant prostate cancer in combination with novel androgen receptor pathway inhibitors (enzalutamide, abiraterone, apalutamide, darolutamide).

MHT/HRT Eligibility: MHT is appropriate for healthy women under the age of 60 (or within 10 years of the menopause) experiencing significant menopausal symptoms, or for women with POI below age 40. NICE NG23 (updated 2023) recommends discussing MHT with all symptomatic menopausal women, emphasising that benefits outweigh risks for most women in this age and time-since-menopause window.

Absolute contraindications to systemic MHT include: oestrogen receptor-positive breast cancer (current or recent); unexplained vaginal bleeding; untreated endometrial cancer; active deep vein thrombosis or pulmonary embolism (or high-risk thrombophilia without adequate anticoagulation); active or recent arterial thromboembolic disease (MI, stroke); severe liver disease with abnormal liver function. Women with a personal history of DVT/PE may safely use transdermal oestrogen (patch or gel), which — unlike oral oestrogen — does not significantly increase VTE risk by avoiding first-pass hepatic metabolism.

Relative contraindications requiring specialist input include: women with high-risk BRCA1/2 mutations; those with prior hormone-sensitive breast cancer who wish to discuss MHT for distressing vasomotor symptoms in the context of specialist oncology and menopause advice; women with cardiovascular risk factors or established cardiovascular disease (transdermal oestrogen preferred).

Gender-Affirming Hormone Therapy (WPATH SOC8 Criteria): WPATH SOC8 (2022) specifies that informed consent — a thorough discussion of expected effects, non-effects, risks, fertility implications, and alternatives — is the central requirement for GAHT in adults. For adolescents, WPATH SOC8 recommends a gender-affirming multidisciplinary care assessment. The previous requirement for letters of referral from mental health professionals has been removed for adults in the SOC8 update, reflecting a shift toward an informed consent model of care.

ADT Eligibility (Prostate Cancer): ADT is initiated based on prostate cancer stage, risk stratification (D’Amico criteria), PSA trajectory, imaging findings (bone scan, PSMA-PET), and patient fitness and preferences. High-risk localised disease, nodal disease, and metastatic disease are the principal indications. ADT combined with radiotherapy (DART, EORTC 22863 trial) has demonstrated significant improvements in overall survival compared to radiotherapy alone in high-risk localised disease.

Menopausal Hormone Therapy (MHT) Regimens:

Women who have had a hysterectomy can take oestrogen alone (oestrogen-only MHT). Women with an intact uterus require progestogen in addition to oestrogen to protect the endometrium from oestrogen-driven hyperplasia and cancer. Sequential (cyclical) combined MHT — continuous oestrogen with progestogen added for 12–14 days per cycle — is preferred for women within 12 months of their last menstrual period and produces a monthly withdrawal bleed. Continuous combined MHT — continuous oestrogen and progestogen — is preferred for women who are at least 12 months post-menopause and produces no planned bleed.

Oestrogen formulations: Transdermal estradiol (patch: 25–100 mcg/24h; gel: 0.5–2 sachets of estradiol 0.06% gel daily; nasal spray: 150 mcg/actuation) avoids first-pass hepatic metabolism and does not increase VTE risk or triglycerides — strongly preferred for women with risk factors for VTE or stroke. Oral oestrogen (estradiol valerate, conjugated equine oestrogen) is suitable for healthy women without VTE risk factors and is the most widely prescribed globally.

Progestogen formulations: Micronised progesterone (Utrogestan) — a body-identical progesterone — is associated with a lower risk of breast cancer than synthetic progestogens (meta-analysis: Lancet 2019) and is now the preferred progestogen in the UK per BMS guidance. Synthetic progestogens (medroxyprogesterone acetate [MPA], norethisterone, dydrogesterone) remain widely used internationally. The levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena) provides effective endometrial protection with minimal systemic absorption.

Gender-Affirming Hormone Therapy (GAHT) — MTF Protocol: Feminising GAHT for transgender women typically combines oestrogen with an anti-androgen. Oestrogen is prescribed as transdermal estradiol (patch or gel) or oral estradiol; injectable oestrogen (e.g., estradiol valerate IM) is used in some jurisdictions. Oestrogen alone — in doses sufficient to suppress endogenous testosterone — is increasingly used without anti-androgen after orchidectomy or with high-dose protocols. Anti-androgens used include: spironolactone (50–200 mg/day; predominantly used in North America); cyproterone acetate (CPA, 12.5–50 mg/day; used widely in Europe, Australia; not FDA-approved in USA); bicalutamide (25–50 mg/day; an androgen receptor blocker increasingly used as a safer alternative with a more favourable side-effect profile than CPA); GnRH agonists (leuprolide, goserelin) used as puberty blockers in adolescents and in adults as a highly effective testosterone suppressor.

Gender-Affirming Hormone Therapy (GAHT) — FTM Protocol: Masculinising GAHT for transgender men uses testosterone as the sole agent, which suppresses hypothalamic-pituitary-gonadal axis function and induces secondary sex characteristics. Formulations include: testosterone gel (Testogel, Tostran — applied daily to the skin); testosterone undecanoate (Nebido — intramuscular injection every 10–14 weeks); testosterone enanthate or cypionate (intramuscular injection every 2–4 weeks); and testosterone patches. WPATH SOC8 target testosterone levels are within the normal male reference range (10–35 nmol/L [300–1000 ng/dL]).

Androgen Deprivation Therapy (ADT) — Prostate Cancer: GnRH agonists (leuprolide [Lupron], goserelin [Zoladex], triptorelin) cause an initial transient testosterone surge (‘flare’) before suppressing LH and testosterone to castrate levels; an antiandrogen (bicalutamide) is co-prescribed for the first 4 weeks to block flare effects in patients with bone metastases at risk of spinal cord compression. GnRH antagonists (degarelix [Firmagon], relugolix [Orgovyx — oral]) suppress testosterone without flare and achieve castration faster (within 3 days). Surgical orchidectomy (bilateral) achieves permanent castration and is a cost-effective alternative with no ongoing medication compliance required; it remains widely used in low- and middle-income countries. Novel androgen receptor pathway inhibitors (abiraterone + prednisone, enzalutamide, apalutamide, darolutamide) are used in combination with ADT in metastatic hormone-sensitive prostate cancer based on survival data from LATITUDE, TITAN, ARAMIS, and ENZAMET trials.

Benefits of MHT/HRT: MHT is the single most effective treatment for menopausal vasomotor symptoms (hot flushes and night sweats), with randomised controlled trials consistently demonstrating 70–90% reductions in flush frequency and severity compared to placebo. Additional evidence-based benefits include: resolution of urogenital atrophy symptoms (vaginal dryness, dyspareunia, recurrent UTIs) — systemic or local vaginal oestrogen is highly effective; improvement in sleep quality, mood, and cognitive function attributable to oestrogen effects on the CNS; prevention and treatment of osteoporosis — MHT reduces fracture risk by approximately 27% (WHI trial data); cardiovascular protection when initiated within 10 years of menopause in healthy women under 60 (the ‘timing hypothesis’ or ‘critical window’ — supported by WHI subgroup analysis, the DOPS trial, and the KEEPS trial).

Premature Ovarian Insufficiency: In POI, MHT reduces the excess cardiovascular risk, preserves bone density, maintains cognitive function, and significantly improves quality of life and sexual wellbeing associated with early oestrogen deficiency.

Benefits of Gender-Affirming Hormone Therapy: Multiple systematic reviews and meta-analyses demonstrate that GAHT significantly improves gender dysphoria, psychological wellbeing, quality of life, and sexual satisfaction in transgender and gender-diverse individuals. A 2020 systematic review by Rana and colleagues documented improvements in anxiety, depression, and body dissatisfaction following GAHT initiation. The Endocrine Society 2017 guidelines and WPATH SOC8 both note that access to GAHT is associated with reduced suicidal ideation and improved mental health outcomes.

Benefits of ADT for Prostate Cancer: ADT induces prostate-specific antigen (PSA) decline in over 90% of hormone-sensitive prostate cancer patients, reduces tumour volume, controls metastatic disease progression, and when combined with radiotherapy or novel antiandrogens, extends overall survival. The ENZAMET trial demonstrated a 5-year overall survival benefit of 67% vs 60% for enzalutamide plus ADT vs ADT alone in metastatic hormone-sensitive prostate cancer.

Risks of MHT/HRT: The primary safety concerns with combined (oestrogen plus progestogen) MHT are: (1) Breast cancer risk — combined MHT is associated with a small increased risk of breast cancer that is related to duration of use. The 2019 Collaborative Group meta-analysis (Lancet, Beral et al.) found that current combined MHT users had a relative risk of approximately 1.6 (compared to 1.0 for never-users), equivalent to approximately 4 additional breast cancer diagnoses per 1,000 women over 5 years of use. Oestrogen-only MHT in women who have had a hysterectomy carries a lower (and possibly slightly protective) effect on breast cancer risk. Micronised progesterone appears to carry a lower breast cancer risk than synthetic progestogens (Lancet 2019 meta-analysis). (2) Venous thromboembolism (VTE) — oral oestrogen increases VTE risk by approximately 2-fold; transdermal estradiol does not increase VTE risk at standard doses. (3) Stroke — oral oestrogen slightly increases the risk of ischaemic stroke; transdermal estradiol does not appear to increase stroke risk at standard doses. (4) Cardiovascular disease — in older women (age 60+) or those more than 10 years post-menopause, MHT initiation may not confer cardiovascular protection and may increase risk, particularly with oral conjugated equine oestrogen combined with MPA.

Risks of GAHT: Feminising GAHT (MTF) risks include: venous thromboembolism (VTE) — oestrogen substantially increases VTE risk, particularly oral oestrogen and at higher doses; hyperprolactinaemia; gallbladder disease; infertility (reversibility uncertain, particularly with prolonged suppression). High-dose cyproterone acetate carries risks of hepatotoxicity, meningioma (risk increases with cumulative dose), and depression. Masculinising GAHT (FTM) risks include: erythrocytosis (polycythaemia — haematocrit above 50% requires dose reduction or phlebotomy); acne; androgenic alopecia (male-pattern hair loss); uterine and vaginal atrophy (increasing risk of vaginal dryness and discomfort); infertility (menstruation typically stops; ovarian function may not fully recover); and unknown long-term cardiovascular risk from testosterone-induced lipid changes.

Risks of ADT: Long-term ADT is associated with well-characterised metabolic and physical side effects including: hot flushes (vasomotor symptoms in 80% of patients); sexual dysfunction (loss of libido and erectile dysfunction in the majority); osteoporosis and increased fracture risk (DEXA surveillance and bisphosphonate or denosumab prophylaxis recommended); metabolic syndrome (weight gain, increased visceral adiposity, insulin resistance, dyslipidaemia); cardiovascular risk (particularly with GnRH agonists — associated with increased risk of MI and sudden cardiac death in men with pre-existing cardiovascular disease); anaemia; fatigue; cognitive changes; and depression. These risks underpin the movement toward intermittent ADT and ADT-free strategies in appropriately selected patients.

Monitoring MHT: NICE NG23 (2023) and the BMS Consensus Statement (2022) recommend an initial follow-up appointment 3 months after starting MHT — to assess symptom control, side effects (breast tenderness, bloating, nausea, irregular bleeding), compliance, and to adjust formulation or dose as needed. Thereafter, annual review is recommended to: reassess the ongoing need for MHT and symptom burden; update the risk-benefit discussion in the context of the woman’s evolving age and health status; ensure breast cancer screening participation; check blood pressure; and review any new personal or family history of breast cancer, cardiovascular disease, or VTE. The BMS explicitly states that there is no arbitrary time limit on MHT duration, rejecting previous guidance suggesting discontinuation at age 60 or after 5 years of use.

Monitoring GAHT — MTF: WPATH SOC8 (2022) and the Endocrine Society Clinical Practice Guideline (2017) recommend monitoring at 3-monthly intervals during the first year of GAHT, then 1–2 times per year thereafter. Parameters monitored include: serum estradiol (target 100–200 pg/mL [370–740 pmol/L] for standard feminising therapy); total testosterone (target below 50 ng/dL [1.7 nmol/L]); full blood count; liver function tests (particularly with cyproterone acetate); renal function; lipid profile; prolactin (6-monthly); body weight and blood pressure. MRI pituitary if prolactin is significantly elevated. Bone density DEXA at age 60 or if risk factors for osteoporosis are present.

Monitoring GAHT — FTM: Monitoring during the first year at 3-monthly intervals, then annually. Parameters include: total testosterone (target 10–35 nmol/L [300–1000 ng/dL]); haematocrit/haemoglobin (polycythaemia risk); lipid profile; liver function; blood pressure; cervical screening — transgender men with a cervix should continue cervical screening per national guidelines; gynaecological examination for vaginal atrophy if symptomatic. Bone density surveillance per clinical risk assessment.

Monitoring ADT for Prostate Cancer: PSA is monitored every 3–6 months — a rising PSA on ADT signals castration-resistant disease or biochemical recurrence. Serum testosterone should be confirmed at castrate levels (below 50 ng/dL or below 1.7 nmol/L) at each assessment. Bone mineral density DEXA at baseline and every 1–2 years; bisphosphonate (zoledronic acid) or denosumab is recommended when osteoporosis is detected or bone metastases are present. Full blood count (anaemia monitoring), lipid profile, and HbA1c (metabolic syndrome screening) should be assessed annually. Cardiovascular risk should be actively managed throughout ADT treatment.

The cost of hormone therapy varies by type, formulation, duration, and healthcare system. For ongoing conditions requiring lifelong or prolonged treatment, cost-effectiveness and access to therapy are important considerations.

MHT Costs (UK): In England, NHS prescriptions for MHT previously attracted the standard NHS prescription charge (£9.90 per item in 2024). Since April 2023, a Hormone Replacement Therapy Prescription Prepayment Certificate (HRT PPC) has been available in England for £32.05 per 12-month period, covering unlimited HRT prescriptions for a full year — significantly reducing out-of-pocket costs for women requiring multiple MHT formulations. In Scotland, Wales, and Northern Ireland, prescriptions are free at the point of care. Private MHT prescriptions in the UK (via menopause clinics) cost £40–£100 per consultation plus medication costs.

MHT Costs (USA): MHT medication costs vary widely. Generic oral estradiol costs $10–$40 per month; branded transdermal patches (Vivelle-Dot, Climara) cost $50–$200 per month without insurance. Prometrium (micronised progesterone) costs $30–$80 per month. Insurance coverage varies by plan; many insurers cover FDA-approved MHT formulations. Compounded bioidentical hormone preparations (often not FDA-regulated) can cost $100–$300 per month and are not covered by most insurers.

GAHT Costs: Testosterone gel for FTM therapy in the UK costs approximately £15–£30 per month on NHS prescription. Oestrogen patches for MTF therapy cost a similar amount. Anti-androgens (spironolactone generically) are inexpensive. In the USA, testosterone therapy without insurance costs $50–$200 per month (gel) or $30–$80 per injection vial. Access to GAHT through gender clinics on the NHS involves long waiting times (often 2–4 years in some regions); private gender medicine providers (e.g., GenderCare, Gender GP) provide faster access at a cost of £150–£250 per initial consultation plus monitoring appointments.

ADT Costs: GnRH agonist injections (e.g., goserelin/Zoladex 3-monthly) cost approximately £300–£600 per injection in the UK private sector; on the NHS, these are provided at standard pharmaceutical pricing. Oral relugolix (Orgovyx) costs approximately $2,000 per month in the USA list price. Novel antiandrogen combinations (abiraterone plus prednisone, enzalutamide) add $5,000–$15,000 per month to ADT costs in the USA without insurance. Surgical orchidectomy — while carrying an upfront surgical cost — eliminates ongoing ADT medication costs and is highly cost-effective for long-term ADT requirements.

Each of the three principal applications of hormone therapy has a range of alternatives appropriate for patients who cannot or prefer not to use hormonal treatment:

Alternatives to MHT for Menopausal Symptoms: Non-hormonal options are recommended by NICE NG23 for women who cannot or prefer not to take MHT. Vasomotor symptoms: SSRIs and SNRIs (venlafaxine 37.5–75 mg/day; paroxetine, escitalopram) reduce hot flush frequency by 50–60% in clinical trials and are first-choice non-hormonal options for symptomatic menopause. Clonidine (an alpha-2 adrenergic agonist) reduces vasomotor symptoms but has a more modest effect size and a side effect profile including dry mouth and drowsiness. Gabapentin and pregabalin significantly reduce night sweats but require careful prescribing due to dependence potential. Fezolinetant (Veoza/Veozah) — a neurokinin 3 receptor antagonist — received FDA approval in 2023 and MHRA approval in 2024 as the first non-hormonal prescription treatment specifically targeting the neuroendocrine pathway driving vasomotor symptoms; clinical trials show approximately 60% reduction in moderate-to-severe hot flush frequency. Cognitive behavioural therapy (CBT) has NICE endorsement for improving menopausal hot flushes and improving quality of life, though it does not reduce objective flush frequency. Urogenital symptoms: Local vaginal oestrogen (pessary, cream, or ring) is highly effective for vaginal dryness, dyspareunia, and recurrent UTIs and has minimal systemic absorption; it can be used in women with a history of breast cancer under specialist guidance. Vaginal moisturisers (Replens, YES VM) and lubricants are effective over-the-counter options.

Alternatives to Gender-Affirming Hormone Therapy: Some non-binary and gender-diverse individuals may achieve sufficient gender affirmation through gender expression, social transition, and psychological support without hormone therapy. Voice training, chest binding or breast augmentation, and gender-affirming clothing and style choices are non-hormonal strategies. For those wishing to feminise without oestrogen, anti-androgen monotherapy (bicalutamide or spironolactone) can reduce androgen-related features without oestrogen. WPATH SOC8 explicitly supports individualised treatment without a mandatory progression through all stages of transition.

Alternatives to ADT for Prostate Cancer: Active surveillance is appropriate for low-risk localised prostate cancer, deferring ADT until clinical or PSA progression. Radical prostatectomy and stereotactic body radiotherapy (SBRT) are curative-intent alternatives to combined ADT and radiotherapy for localised disease. Intermittent ADT — cycling periods of treatment with treatment-free intervals — is an evidence-based strategy that reduces cumulative ADT side effects while maintaining oncological outcomes in appropriately selected men with non-metastatic disease. High-intensity focused ultrasound (HIFU) and cryotherapy are ablative alternatives for localised disease in selected patients.